Abstract
Galanin-like peptide(GALP) was discovered in the porcine hypothalamus in 1999 and it was found to be a 60 amino-acid peptide. Administration of GALP is well known to decrease food intake and body weight. In addition, it is also shown to increase core body temperature and energy metabolism after intraventricular infusion. Therefore, GALP may be a potential therapeutic medicine to be sued for the treatment of life-related diseases. This review summarizes the current evidence regarding the function of GALP, particularly in relation to feeding and energy metabolism. Moreover, intranasal administration of GALP is an effective route for delivery to the brain. We have examined the effect of GALP on food intake, body weight and energy metabolism after intranasal infusion which is a clinically viable route of delivery. We will present here that GALP may be used for obese people and also be helpful to overcome life-style-related diseases in the near future.
